<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Decitabine and cedazuridine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Decitabine and cedazuridine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Decitabine and cedazuridine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="128968" href="/d/html/128968.html" rel="external">see "Decitabine and cedazuridine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54733054"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Inqovi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F54829653"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Inqovi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54523951"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antimetabolite;</li>
<li>
                        Antineoplastic Agent, DNA Methylation Inhibitor;</li>
<li>
                        Cytidine Deaminase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54675936"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Do not substitute decitabine/cedazuridine oral tablets for IV decitabine within a treatment cycle. Administer anti-infective prophylaxis as clinically appropriate. Consider the use of antiemetics prior to each decitabine/cedazuridine dose. Begin next cycle only if ANC ≥1,000/mm<sup>3</sup> and platelets ≥50,000/mm<sup>3</sup> (in the absence of active disease).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a0f632d-b77e-4ef6-9713-61ec39c1b72d">Myelodysplastic syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myelodysplastic syndromes: Oral:</b> Decitabine 35 mg/cedazuridine 100 mg once daily on days 1 to 5 of each 28-day treatment cycle for a minimum of 4 cycles, until disease progression or unacceptable toxicity. May take longer than 4 cycles for a complete or partial response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Garcia.1','lexi-content-ref-32285126','lexi-content-ref-Savona.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Garcia.1','lexi-content-ref-32285126','lexi-content-ref-Savona.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If a dose is missed within 12 hours of the time it is usually administered, administer the missed dose as soon as possible and then resume the normal daily dosing schedule. Extend the dosing period by 1 day for every missed dose to complete 5 daily doses for each cycle. If a dose is vomited, do not administer an additional dose (continue with the next scheduled dose).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54675938"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Kidney function may be estimated using the Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 to 59 mL/minute: No dosage adjustment necessary; monitor for increased incidence of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;15 mL/minute (end-stage kidney disease): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Acute kidney toxicity during treatment:</i> Serum creatinine ≥2 mg/dL: Delay the next cycle and resume at the same or at a reduced dose (eg, administer fewer days per cycle) upon resolution.</p></div>
<div class="block doha drugH1Div" id="F54675939"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Initial dose titration in patients with preexisting hepatic impairment</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN): There are no dosage adjustments provided in the manufacturer’s labeling; however, mild impairment had no effect on decitabine or cedazuridine pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) to severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Acute hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin ≥2 times ULN: Delay the next cycle and resume at the same or at a reduced dose (eg, administer fewer days per cycle) upon resolution.</p>
<p style="text-indent:-2em;margin-left:4em;">AST or ALT ≥2 times ULN: Delay the next cycle and resume at the same or at a reduced dose (eg, administer fewer days per cycle) upon resolution.</p></div>
<div class="block dot drugH1Div" id="F54675940"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Decitabine/Cedazuridine Recommended Dosage Reduction Levels for Hematologic Toxicity</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Usual (initial) dose</p></td>
<td align="center">
<p style="text-indent:0em;">Decitabine 35 mg/cedazuridine 100 mg once daily on days 1 through 5 of a 28-day treatment cycle</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Dose Reduction Level</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>Decitabine/Cedazuridine Dose Reduction Schedule</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">First</p></td>
<td align="center">
<p style="text-indent:0em;">Decitabine 35 mg/cedazuridine 100 mg once daily on days 1 through 4</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Second</p></td>
<td align="center">
<p style="text-indent:0em;">Decitabine 35 mg/cedazuridine 100 mg once daily on days 1 through 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Third</p></td>
<td align="center">
<p style="text-indent:0em;">Decitabine 35 mg/cedazuridine 100 mg once daily on days 1, 3, and 5</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Decitabine/Cedazuridine Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Decitabine/cedazuridine dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> In the absence of active disease.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>b</sup> Hematologic recovery: ANC ≥1,000/mm<sup>3</sup> and platelets ≥50,000/mm<sup>3</sup>.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Hematologic toxicity</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup> (grade 3)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold decitabine/cedazuridine and monitor CBC as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Administer supportive care (growth factors and anti-infectives) for persistent severe neutropenia or febrile neutropenia as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Resume next cycle when ANC ≥1,000/mm<sup>3</sup> and platelets ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Hematologic recovery<sup>b</sup> within 2 weeks of achieving remission:</i> Continue decitabine/cedazuridine at same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Hematologic recovery<sup>b</sup> does not occur within 2 weeks of achieving remission:</i> Withhold decitabine/cedazuridine for up to 2 additional weeks; resume at reduced dose (administration on days 1 to 4). Consider further dose reduction if bone marrow suppression continues. Reduced dose may be continued or increased in subsequent cycles as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup> (grade 3)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold decitabine/cedazuridine and monitor CBC as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Resume next cycle when ANC ≥1,000/mm<sup>3</sup> and platelets ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Hematologic recovery<sup>b</sup> within 2 weeks of achieving remission:</i> Continue decitabine/cedazuridine at same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Hematologic recovery<sup>b</sup> does not occur within 2 weeks of achieving remission:</i> Withhold decitabine/cedazuridine for up to 2 additional weeks; resume at reduced dose (administration on days 1 to 4). Consider further dose reduction if bone marrow suppression continues. Reduced dose may be maintained or increased in subsequent cycles as clinically indicated.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Nonhematologic toxicity </b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Infection</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any active or uncontrolled</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold decitabine/cedazuridine; administer anti-infective treatment and prophylaxis as clinically indicated.</p>
<p style="text-indent:0em;text-align:left;">Upon resolution, resume at same dose or reduced dose (eg, administer fewer days per cycle).</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54675937"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F54569812"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. Also see decitabine.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (22%), decreased serum calcium (16%), decreased serum glucose (14%), increased serum glucose (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (20%), diarrhea (16%), nausea (25%), stomatitis (18%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (71%; grades 3/4: 55%), febrile neutropenia (10% to 33%; grades 3/4: 10% to 32%), hemorrhage (24%; grades 3/4: 2%), leukopenia (79%; grades 3/4: 65%), neutropenia (73%; grades 3/4: 71%), thrombocytopenia (82%; grades 3/4: 76%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (13%), increased serum alkaline phosphatase (22%), increased serum transaminase (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (6% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (16%), fatigue (29%), headache (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (17%), pneumonia (7% to 21%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (3%), edema (10%), hypotension (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cellulitis (4%), Sweet’s syndrome (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum sodium (9%), weight loss (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (9%), decreased appetite (10%), vomiting (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Falling (4%), insomnia (6%), neuropathy (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (9%), myalgia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (7%), renal insufficiency (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (7%), upper respiratory tract infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hematologic &amp; oncologic: Tumor lysis syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Differentiation syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease</p></div>
<div class="block coi drugH1Div" id="F54523954"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to decitabine, cedazuridine, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54675924"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Fatal and serious myelosuppression can occur with decitabine/cedazuridine. New or worsening thrombocytopenia (including grades 3 or 4) occurred commonly. Neutropenia and anemia (including grades 3 or 4) were also common. Neutropenic fever occurred in one-third of patients; grades 3 or 4 neutropenic fever events were reported. Myelosuppression and worsening neutropenia may occur more frequently in the first or second treatment cycles and may not necessarily indicate progression of underlying myelodysplastic syndromes. Hematologic toxicity (thrombocytopenia, neutropenia, anemia, and febrile neutropenia) is the most frequent cause of decitabine/cedazuridine treatment interruption and/or dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious and sometimes fatal complications due to infection have occurred with decitabine/cedazuridine. Pneumonia and sepsis have been observed, including grade 3 or 4 events; rare fatalities due to pneumonia, sepsis, and septic shock were also reported.</p></div>
<div class="block foc drugH1Div" id="F54733055"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inqovi: 35-100 MG</p></div>
<div class="block geq drugH1Div" id="F54733053"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54783494"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Inqovi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35-100 mg (per each): $1,982.82</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F54829654"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inqovi: 35-100 MG</p></div>
<div class="block accres drugH1Div" id="F58659516"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Decitabine/cedazuridine is available through specialty distributors, specialty pharmacies, and various specialty institutions/accounts. Examples from the manufacturer may be found at https://www.inqovi.com/Content/pdf/pharmacy-guide.pdf.</p></div>
<div class="block adm drugH1Div" id="F54675941"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at approximately the same time of day. Swallow tablet whole; do not cut, crush, or chew. Administer on an empty stomach; do not consume food 2 hours before and 2 hours after dose. Consider the use of antiemetics prior to each decitabine/cedazuridine dose.</p></div>
<div class="block hazard drugH1Div" id="F54675926"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Decitabine is a hazardous agent (NIOSH 2016 [group 1]); decitabine/cedazuridine is a cytotoxic drug (per product labeling).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F54523953"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Myelodysplastic syndromes:</b> Treatment of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups, in adults.</p></div>
<div class="block mst drugH1Div" id="F54675918"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54582094"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54582091"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cedazuridine: May increase the serum concentration of Cytidine Deaminase Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cytidine Deaminase Substrates: Cedazuridine may increase the serum concentration of Cytidine Deaminase Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54675920"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 6 months after the last dose of decitabine/cedazuridine. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last decitabine/cedazuridine dose.</p></div>
<div class="block pri drugH1Div" id="F54675919"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action, data from animal reproduction studies, as well as limited human data, in utero exposure to decitabine/cedazuridine may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54675921"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if decitabine or cedazuridine are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 2 weeks after the last decitabine/cedazuridine dose.</p></div>
<div class="block mop drugH1Div" id="F54675943"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor CBC (at baseline, prior to each cycle, and as clinically indicated); monitor serum creatinine, CrCl, AST, ALT, total bilirubin. Evaluate pregnancy status prior to use (in patients who could become pregnant). Monitor for signs/symptoms of infection. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54675928"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Decitabine is a hypomethylating agent. After phosphorylation, decitabine is incorporated into DNA and inhibits DNA methyltransferase causing hypomethylation and subsequent cell death (within the S-phase of the cell cycle). Hypomethylation in cancer cells may restore normal function to genes that are necessary for control of cellular differentiation and proliferation.</p>
<p style="text-indent:-2em;margin-left:2em;">Cedazuridine is a cytidine deaminase (CDA) inhibitor. CDA is an enzyme that catalyzes the degradation of cytidine, including the cytidine analog decitabine; high CDA levels in the GI tract and liver degrade decitabine and limit its oral bioavailability. The combination of cedazuridine with decitabine increases systemic decitabine exposure.</p></div>
<div class="block phk drugH1Div" id="F54675929"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V/F<sub>ss</sub> (apparent): Decitabine: 417 L; Cedazuridine: 296 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Decitabine: Primarily via cytidine deaminase, also via physiochemical degradation; Cedazuridine: Conversion to epimer via physiochemical degradation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Decitabine: Cedazuridine increases oral decitabine exposure; Cedazuridine: 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Decitabine: 1.5 hours; Cedazuridine: 6.7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Decitabine: 1 hour (range: 0.3 to 3 hours); Cedazuridine: 3 hours (range: 1.5 to 6.1 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Cedazuridine: Feces (51%; 27% as unchanged drug); Urine (46%; 21% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (apparent): Decitabine: 197 L/hour; Cedazuridine: 30.3 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522130"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Inqovi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Inqovi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32285126">
<a name="32285126"></a>Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. <i>Blood</i>. 2020;136(6):674-683. doi:10.1182/blood.2019004143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/decitabine-and-cedazuridine-drug-information/abstract-text/32285126/pubmed" id="32285126" target="_blank">32285126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garcia.1">
<a name="Garcia.1"></a>Garcia-Manero G, McCloskey J, Griffiths EA, et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine/decitabine) compared to IV decitabine. <i>Blood.</i> 2019;134(suppl 1):846. doi:10.1182/blood-2019-122980</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/decitabine-and-cedazuridine-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Inqovi (decitabine and cedazuridine) [prescribing information]. Princeton, NJ: Taiho Oncology Inc; July 2020.</div>
</li>
<li>
<div class="reference">
                  Inqovi (decitabine and cedazuridine) [prescribing information]. Princeton, NJ: Taiho Oncology Inc; March 2022.</div>
</li>
<li>
<div class="reference">
                  Inqovi (decitabine and cedazuridine) [product monograph]. Oakville, Ontario, Canada: Taiho Pharma Canada Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Savona.1">
<a name="Savona.1"></a>Savona MR, McCloskey JK, Griffiths EA, et al. Efficacy of oral decitabine/cedazuridine (ASTX727) in the CMML subgroup from the ASCERTAIN phase 3 study. <i>Blood.</i> 2021;138(suppl 1):3682. doi:10.1182/blood-2021-154179</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed July 17, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 128935 Version 56.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
